Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 657

Results For "CE"

8917 News Found

Dr. Reddy’s completes clinical studies of its rituximab biosimilar for filing in the U.S., Europe
Drug Approval | January 21, 2023

Dr. Reddy’s completes clinical studies of its rituximab biosimilar for filing in the U.S., Europe

Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions


G 20: Medical Value Travel could be focused on maintaining, improving or restoring health through medical intervention: Dr V K Paul
Policy | January 21, 2023

G 20: Medical Value Travel could be focused on maintaining, improving or restoring health through medical intervention: Dr V K Paul

There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare


Marksans Pharma raises Rs. 372.40 crores
News | January 21, 2023

Marksans Pharma raises Rs. 372.40 crores

OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.


Innova Captab gets SEBI nod to raise funds via IPO
News | January 20, 2023

Innova Captab gets SEBI nod to raise funds via IPO

The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore


Blue Jet Healthcare gets SEBI nod for IPO
News | January 20, 2023

Blue Jet Healthcare gets SEBI nod for IPO

The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.


Mandaviya urges stakeholders to partner with India to leverage opportunities at WEF Davos
News | January 19, 2023

Mandaviya urges stakeholders to partner with India to leverage opportunities at WEF Davos

India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery


Lupin launches Sacubitril and Valsartan combination drug for heart failure patients
News | January 19, 2023

Lupin launches Sacubitril and Valsartan combination drug for heart failure patients

Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure


USFDA completes inspection at APL HealthCare
Drug Approval | January 19, 2023

USFDA completes inspection at APL HealthCare

The company has been issued ‘Form 483’ with two observations


Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets
News | January 18, 2023

Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets

Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)


Glenmark to divest select dermatology brands for Rs. 340.48 Cr
News | January 18, 2023

Glenmark to divest select dermatology brands for Rs. 340.48 Cr

The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands